A Trial to Develop Peptide Vaccine for Strongyloidiasis
类圆线虫病肽疫苗的开发试验
基本信息
- 批准号:02557022
- 负责人:
- 金额:$ 2.82万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Developmental Scientific Research (B)
- 财政年份:1990
- 资助国家:日本
- 起止时间:1990 至 1991
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Because of limitted availability of Strongyloides stercoralis and because of antigenic complexity, initially our aim of gene cloning was focused on the neutrophil chemotactic factor (NCF) of S. ratti (Sr). By using combination of DE52 ion exchange colum chromatography and SW3000 HPLC or Procion Red affinity chromatograophy, we obtained NCF as a single protein peak. However, this peak was still heterogenous by SDS-PAGE. Furthermore, an attempt to make cDNA library was failed because only about 5000 clones were established from mRNA of Sr-L_3. As an alternative approach, therefore, Dirofilaria immitis (Di) NCF was used as the stating material because it has been already purified by our hand, and Di-NCF epitopes were expressed in several antigenic components of Sr including Sr-NCF by Western-blot analysis. Poly-A-RNA was isolated from Di adult worms and the cDNAs were inserted into EcoRI site of lambdagT11. About 2 x 10^5 clones produced as the cDNA library were further selected by using … More anti-Di-NCF. The phage DNAs of positive clones were purified, fragmented by EcoRI, and clones having 0.7-2.0 Kb inserts were subcloned in to a plasmid vector Bluescript SK(-). Their DNA sequences were determined by dideoxy method using M13 primer. In parallel, N-terminal 45 amino acid sequence of purified Di-NCF was determined by antomatic sequencer. When the expected amino acid sequences from the DNA sequences of four subclones were compared to the actual N-terminal amino acid sequences, subclone named pD4 showed complete homology at the DNA sequence of 268-402 from 5' terminal. Open rcading frame was 166-606 coding the leader sequence of 34 amino acid residues and the Di-NCF sequence of 112 amino acid recidues. By comoputer -aided homology search, 99-101 amino acid sequence (Met-Phe-Lys) had a similarity to known NCF peptide so that this sequence was thougt as the epitope of active site of the Di-NCF. In fact, synthesised Met-Phe-Lys and also fMet-Phe-Lys showed NCF activity at the concentrations lower than of known NCF peptides. The clone pD4 was subcloned into plasmid vector pGEM EX and fusion protein with gene 10 was produced. This fusion protein showed NCF activity and antigenicity similar to those of purified Di-NCF. When mice were immunized with this fusion protein, their susceptibility against Brugia pahagi rather increased, suggesting the induction of blocking antibody or suppressor system. Further study is required as to the methods of immunization. Less
由于粪类圆线虫的可利用性有限以及抗原的复杂性,最初我们的基因克隆目标集中在嗜中性粒细胞趋化因子(NCF)。ratti(Sr).采用DE 52离子交换柱层析和SW 3000高效液相色谱或Procion Red亲和层析相结合的方法,得到了单一蛋白峰的NCF。然而,通过SDS-PAGE,该峰仍然是异质的。此外,Sr-L_3的cDNA文库构建也失败了,仅构建了约5000个克隆。因此,作为一种替代方法,使用犬恶丝虫(Di)NCF作为起始材料,因为它已经由我们的手纯化,并且通过Western印迹分析,Di-NCF表位在Sr的几种抗原组分中表达,包括Sr-NCF。从Di蠕虫中提取Poly-A-RNA,并将cDNA插入到AgdagT 11的EcoRI位点。通过使用PCR进一步选择作为cDNA文库产生的约2 × 10^5个克隆。 ...更多信息 抗Di-NCF。纯化阳性克隆的噬菌体DNA,用EcoRI片段化,将具有0.7- 2.0Kb插入片段的克隆亚克隆到质粒载体BluescriptSK(-)中。用M13引物双脱氧法测定其DNA序列。同时,通过测序仪测定纯化的Di-NCF的N-末端45个氨基酸序列。当将来自四个亚克隆的DNA序列的预期氨基酸序列与实际N-末端氨基酸序列进行比较时,命名为pD 4的亚克隆在5'末端的268-402的DNA序列处显示出完全同源性。开放阅读框为166-606,编码34个氨基酸的前导序列和112个氨基酸的Di-NCF序列。通过计算机同源性搜索,发现99-101个氨基酸序列(Met-Phe-Lys)与已知的NCF肽段具有相似性,因此认为该序列是Di-NCF活性位点的表位。事实上,合成的Met-Phe-Lys以及fMet-Phe-Lys在低于已知NCF肽的浓度下显示出NCF活性。将克隆pD 4亚克隆到质粒载体pGEM EX中,并产生与基因10的融合蛋白。该融合蛋白具有与纯化的Di-NCF相似的NCF活性和抗原性。当用该融合蛋白免疫小鼠时,它们对巴氏丝虫的易感性反而增加,这表明诱导了封闭抗体或抑制系统。需要进一步研究免疫接种的方法。少
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
大橋 真: "寄生虫ワクチン開発の現状" 第16回日本熱帯医学会九州支部大会シンポジウム記録. (1992)
大桥诚:第16届日本热带医学会九州分会会议《寄生虫疫苗开发现状》研讨会记录(1992年)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Owhahsi, M., Kitagawa, K., Horii, Y., Maruyama, H., Hayashi, H. and Nawa Y.: "Molecular cloning and characterization of the neutrophil chemotactic factor derived from Dilofilaria immitis." J. Immunol.
Owhahsi, M.、Kitakawa, K.、Horii, Y.、Maruyama, H.、Hayashi, H. 和 Nawa Y.:“源自 Dilofilaria immitis 的中性粒细胞趋化因子的分子克隆和表征。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
大橋 真,堀井 洋一郎,丸山 治彦,名和 行文: "犬糸状虫由来好中球遊走因子cDNAのクロ-ニングと分子構造の解析" Jpn.J.Parasitol(寄生虫学雑誌). 40(Suppl). 89 (1991)
Makoto Ohashi、Yoichiro Horii、Haruhiko Maruyama、Yukifumi Nawa:“源自犬恶丝虫的中性粒细胞趋化因子 cDNA 的分子结构的克隆和分析”Jpn.J.Parasitol(Parasitol 杂志)40(增刊)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
大橋 真: "寄生虫ワクチン開発の現状" 投稿中(雑誌未定)第16回日本熱帯医学会九州支部大会シンポジウム記録. (1992)
大桥诚:“寄生虫疫苗开发现状”提交(期刊未定)第16届日本热带医学会九州分会会议记录(1992年)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Owhashi, M., Morii, Y., Maruyama, H. and Nawa, Y.: "Molecular cloning and characterization of neutrophil chemotactic factor derived from Dilofiralia immitis." Proc. Ann. Meeting Jpn. Soc. Immunol.20. 264 (1990)
Owhashi, M.、Morii, Y.、Maruyama, H. 和 Nawa, Y.:“源自 Dilofiralia immitis 的中性粒细胞趋化因子的分子克隆和表征。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAWA Yukifumi其他文献
NAWA Yukifumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAWA Yukifumi', 18)}}的其他基金
Seroepidemiological study on Ascaris suum infection in humans, an emerging zoonosis causing visceral larva migrans
人类猪蛔虫感染的血清流行病学研究,一种引起内脏幼虫移行症的新出现的人畜共患病
- 批准号:
09470070 - 财政年份:1997
- 资助金额:
$ 2.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Protective role of small intestinal mucin producing cells against intestinal helminths
小肠粘蛋白产生细胞对肠道蠕虫的保护作用
- 批准号:
03670198 - 财政年份:1991
- 资助金额:
$ 2.82万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
Natural Life Cycle of Gnathostoma Doloresi in Miyazaki Prefecture, with Emphasis on the Route of Infection to the Patients.
宫崎县多洛雷氏颚口虫的自然生命周期,重点是患者的感染途径。
- 批准号:
01570217 - 财政年份:1989
- 资助金额:
$ 2.82万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
新生期接种乙肝疫苗(hepatitis B vaccine,HBV)影响小鼠情绪相关行为及其机制研究
- 批准号:31600836
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
A Peptide-mRNA Vaccine for Crimean-Congo Haemorrhagic Fever (CCHF)
克里米亚-刚果出血热 (CCHF) 的肽 mRNA 疫苗
- 批准号:
10026224 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
Small Business Research Initiative
A Phase 1 Clinical Trial of a Peptide-Based Group A Streptococcal Vaccine
基于肽的 A 组链球菌疫苗的 1 期临床试验
- 批准号:
466323 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
Operating Grants
Intranasal delivery of cancer vaccine combined with cell-penetrating peptide and longer tumor antigens for bladder cancer
鼻内递送癌症疫苗结合细胞穿透肽和更长的肿瘤抗原治疗膀胱癌
- 批准号:
22K09501 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
沃拉西尼联合肿瘤特异性肽 PEP-IDH1M 疫苗治疗复发性突变 IDH1 胶质瘤患者的临床评价和无创监测
- 批准号:
10707909 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
A Phase 1 Clinical Trial of a Peptide-Based Group A Streptococcal Vaccine
基于肽的 A 组链球菌疫苗的 1 期临床试验
- 批准号:
474602 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
Operating Grants
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
沃拉西尼联合肿瘤特异性肽 PEP-IDH1M 疫苗治疗复发性突变 IDH1 胶质瘤患者的临床评价和无创监测
- 批准号:
10419216 - 财政年份:2022
- 资助金额:
$ 2.82万 - 项目类别:
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers
开发治疗 KRAS 突变癌症的肽疫苗的新范例
- 批准号:
10438897 - 财政年份:2021
- 资助金额:
$ 2.82万 - 项目类别:
HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles
使用病毒样颗粒进行 HIV-1 融合肽定向疫苗设计
- 批准号:
10257205 - 财政年份:2021
- 资助金额:
$ 2.82万 - 项目类别:
HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles
使用病毒样颗粒进行 HIV-1 融合肽定向疫苗设计
- 批准号:
10574489 - 财政年份:2021
- 资助金额:
$ 2.82万 - 项目类别:
Gonococcal peptide vaccine candidate display using HPV virus-like particles
使用 HPV 病毒样颗粒展示候选淋球菌肽疫苗
- 批准号:
10390991 - 财政年份:2021
- 资助金额:
$ 2.82万 - 项目类别:














{{item.name}}会员




